Skip Navigation LinksHome > Collections > Anti-CTLA4 (ipilimumab & tremelimumab)

Anti-CTLA4 (ipilimumab & tremelimumab)

Created:   6/14/2011
Contains:  10 items
Anti-CTLA4 (ipilimumab & tremelimumab9)

Actions
View

Restoration of tumor equilibrium after immunotherapy for advanced melanoma: three illustrative cases

Purchase Access
Abstract
PDF
+ Favorites
Request Permissions

An update on UV-induced carcinogenesis

Free Access
PDF
+ Favorites
Request Permissions

Complete regression of a previously untreated melanoma brain metastasis with ipilimumab

Purchase Access
Abstract
PDF
+ Favorites
Request Permissions

Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma

Purchase Access
Abstract
PDF
+ Favorites
Request Permissions

Vaccine immunotherapy and prognostic factors of success: where we are today?

Free Access
PDF
+ Favorites
Request Permissions

Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient

Purchase Access
Abstract
PDF
+ Favorites
Request Permissions

INV 24 Historic overview and review of current strategies of adjuvant therapy for high-risk melanoma

Purchase Access
PDF
+ Favorites
Request Permissions

Editorial: anticytotoxic T lymphocyte-associated antigen 4 treatment – can melanoma be cured at the expense of autoimmune disorders?

Purchase Access
PDF
+ Favorites
Request Permissions

The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies

Purchase Access
Abstract
PDF
+ Favorites
Request Permissions

Biochemotherapy in metastatic melanoma: quo vadis?

Purchase Access
PDF
+ Favorites
Request Permissions
Actions
View
Collection Alerts

Stay up-to-date! Be notified every time a new item is added. Receive an Email or subscribe to an RSS feed.